State-of-the-art cancer treatment: • Chemotherapy and radiation facilities • On-site radiology and interventional radiology at the Medical Center office • The largest Phase I oncology clinical trials program in the world • State-of-the-art electronic medical records which allows for fully integrated centers
State-of-the-art radiation technology: • The CyberKnife - the only center in South Texas to offer this innovation • Trilogy Accelerator with RAPIDARC • Image Guided Radiation Therapy (IGRT) using On Board Imaging and Cone Beam CT • Intensity Modulated Radiation Therapy (IMRT)
Internationally recognized cancer research program START’s pre-clinical and research department is one of the most advanced in the world, and was created to accelerate the development of new anticancer drugs with the purpose of improving quality of life and survival for patients with cancer. START’s Phase I program has recently launched a one-of-a-kind open-access Tumor Bank, and Phase 1 programs in Madrid, Spain and Shanghai, China.
A patient advocacy program Gives patients and their representatives one person to serve as the ambassador for the cancer center, bonding a partnership between the cancer center and the patient.
The Cure STARTs Here
Steven Abbate, M.D.
Shelly Gunn M.D., Ph.D.
Gladys Rodriguez, M.D.
Mayo Clinic Medical School and Surgical Residency at Harvardâ€™s Massachusetts General Hospital Gastrointestinal, endocrine, breast and cancer surgery with a clinical interest in cancers of the stomach and pancreas. Certified by the American Board of Surgery and a Fellow of the American College of Surgery.
UTHSCSA Medical School and Graduate School of Biomedical Sciences with a clinical pathology residency at UTHSCSA Clinical focus is the delivery of personalized cancer care to patients through genetic testing of hematological malignancies and solid tumors, with a specialty in breast cancer genome analysis. Board Certified in Clinical Pathology.
University of Puerto Rico, School of Medicine Clinical interests include cancer treatment and new drug therapy for cancer
General Surgery & Surgical Oncology
Ardow R. Ameduri, M.D.
Joseph Holahan, M.D.
Luis Carlos Rodriguez, M.D.
New York Medical College Specializes in Prostate Cancer with Brachytherapy and IMRT, and the CyberKnife
University of Florida Board Certified in Hematology
University of Texas Health Science Center at San Antonio Special interest in gastrointestinal malignancies and breast cancer
Murali Beeram, M.D., M.B.B.S.
Steven P. Kalter, M.D.
Marisa Sanders, M.D.
Osmania Medical College, India Board Certified Medical Oncologist and Clinical Investigator
Baylor College of Medicine Board Certified in Internal Medicine, Hematology and Medical Oncology
University of Texas Health Science Center at San Antonio General Medical Oncology
Ronald L. Drengler, M.D.
Amy Lang, M.D.
Lon S. Smith, M.D.
National University of Paraguay Specializes in General Medical Oncology with a special interest in clinical trials
University of Texas Health Science Center San Antonio Board Certified in Internal Medicine and Medical Oncology
LSU Medical School Principal investigator of clinical trials involving the Pancreatic Cancer Research Team
Keith E. Eyre, M.D.
James Mark, M.D.
Scott Ulmer, M.D.
Texas Tech University Specializes in CyberKnife, Gamma Knife, brain and breast cancers
University of Maryland School of Medicine, Baltimore, Maryland Board Certified in Obstetrics and Gynecology
University of Utah Huntsman Cancer Institute Board Certified in Hematology and Medical Oncology
Medical Oncology and Hematology
Lisa Fichtel, M.D.
Alexander Miller, M.D.
Allen James White, M.D.
UT Southwestern Clinical interests include general Medical Oncology with special interest in brain tumors and breast cancer
Trained in cancer surgery at MD Anderson Cancer Center, Houston, TX Specialized in breast cancer, melanoma and skin cancer, pancreatic and gastric cancer, and sarcoma
State University of New York in Brooklyn Board Certified in Gynecologic Oncology, Obstetrics and Gynecology
General Surgery & Surgical Oncology
Allison M. Garner, M.D., Ph.D.
Joaquin Mira, M.D.
Sylvia Zubyk, M.D.
University of Texas Health Science Center at San Antonio Specializes in General Medical Oncology
University of Madrid Spain Clinical interests include General Radiation Therapy and cancers of the lung, breast, prostate, and brain. Proficient in Gynecological and Head and Neck implants, IMRT, Radiosurgery and Brachytherapy
University of Texas Medical Branch, Galveston Board Certified in Radiation Oncology with special interest in breast cancer
The mission of START is to accelerate the development of new anti-cancer drugs with the purpose of improving the quality of life and survival for patients with cancer. START consists of a team of highly trained physicians and staff, with extensive experience in Phase 1 clinical trials research. Amita Patnaik, M.D., FRCPC
START Research - Clinical Investigator Clinical interests include malignancies of the gastrointestinal tract and anticancer drug development
Kyriakos Papadopoulos, M.D., MSc, FCP(SA) START Research - Clinical Investigator Clinical interests include drug development and malignancies of the gastrointestinal tract and lungs
Drew W. Rasco, M.D.
START Research - Clinical Investigator University of Texas Health Science Center at San Antonio, and Internal Medicine residency at the Emory University School of Medicine in Atlanta, GA, followed with fellowships in Hematology and Oncology at the University of Texas, Southwestern Medical Center in Dallas. Board Certified in Internal Medicine
Anthony Tolcher, M.D., FRCPC
START Research - Clinical Investigator University of British Columbia Special interest in molecular genetic targets for cancer therapy
START’s pre-clinical and research department is one of the most advanced in the world, and was created to accelerate the development of new...